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Abstract
Background: Long non-coding RNAs (lncRNAs) play a variety of cellular roles, including regulation of transcription
and translation, leading to alterations in gene expression. Some lncRNAs modulate the expression of
chromosomally adjacent genes. Here, we assess the roles of the lncRNA CASC15 in regulation of a chromosomally
nearby gene, SOX4, and its function in RUNX1/AML translocated leukemia.
Results: CASC15 is a conserved lncRNA that was upregulated in pediatric B-acute lymphoblastic leukemia (B-ALL)
with t (12; 21) as well as pediatric acute myeloid leukemia (AML) with t (8; 21), both of which are associated with
relatively better prognosis. Enforced expression of CASC15 led to a myeloid bias in development, and overall,
decreased engraftment and colony formation. At the cellular level, CASC15 regulated cellular survival, proliferation,
and the expression of its chromosomally adjacent gene, SOX4. Differentially regulated genes following CASC15
knockdown were enriched for predicted transcriptional targets of the Yin and Yang-1 (YY1) transcription factor.
Interestingly, we found that CASC15 enhances YY1-mediated regulation of the SOX4 promoter.
Conclusions: Our findings represent the first characterization of this CASC15 in RUNX1-translocated leukemia, and
point towards a mechanistic basis for its action.
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Background
Among the several classes of non-coding RNA species be-
ing described, long non-coding RNAs are notable for their
status as unique gene structures [1]. The majority of
lncRNAs is characterized by capped, polyadenylated, and
spliced transcripts that lack an open reading frame. Genes
encoding lncRNAs show positional conservation in the
genome and contain very short stretches of highly con-
served sequences between species [1–3]. Despite the simi-
larities in their genetic organization, there is a great deal
of variation in the functions of different lncRNAs. They
play a variety of roles at the cellular level, including regu-
lation of transcription and translation, leading to
alterations in gene expression. One of these functions is
the regulation of gene expression in cis, which results in
the modulation of expression of chromosomally adjacent
genes upon knockdown or overexpression of lncRNAs [4].
Our recent work has identified a list of lncRNAs that
are differentially expressed in pediatric B-lymphoblastic
leukemia (B-ALL) patient samples [5]. One of the
lncRNAs from our study, annotated as CASC15, (previ-
ously annotated as LINC00340) was of particular interest
as it neighbors the protein coding gene, SOX4. SOX4 was
first identified as a transcriptional activator in lymphocytes
and plays an essential role in B-cell development [6, 7].
Recent studies have shown involvement of SOX4 in many
human malignancies, including the hematopoietic system
[8, 9]. CASC15 was recently described in two other types
of cancer: neuroblastoma and melanoma. It is lost as part
of the chromosome 6p22 deletion in neuroblastoma, and
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plays a role as a tumor suppressor gene in neuroblastoma
cell lines [10]. Interestingly, a second study demon-
strated that CASC15 was associated with metastatic
melanoma and siRNA-mediated knockdown resulted
in altered growth and metastatic properties of melanoma-
derived cell lines [11]. These two studies suggest some-
what different roles for CASC15, with an anti-proliferative
phenotype in neuroblastoma, but a pro-metastatic role in
melanoma.
In this study, we sought to delineate the function of
CASC15 in acute leukemia. CASC15 expression was
high in acute leukemia with RUNX1 translocations, and
its expression in cells led to increased apoptosis and de-
creased engraftment in the hematopoietic system. Our
experiments also demonstrated the efficacy of knock-
down of a lncRNA by using the recently described
CRISPR/Cas9 system, adapted for this specific purpose.
At the molecular level CASC15 regulates SOX4 expres-
sion and downstream gene expression mediated by this
transcription factor. Finally, the mechanism of action of
CASC15 appears to involve modulation of gene expres-
sion by the transcription factor Yin and Yang-1 (YY1).
These studies provide important insights into lncRNA
function in the hematopoietic system.
Methods
Patients and samples
B- ALL patient samples were previously described [5].
Briefly, the B-ALL patient cohort consisted of children
consecutively admitted to the Pediatric Oncologic De-
partment at the University of Padua, Italy, from 2000 to
2008 with the diagnosis of B-ALL. A total of 125 patient
samples used for qPCR consisted of 39 ETV6-RUNX1, 8
E2A-PBX, 16 MLL-rearranged, 3 BCR-ABL and 59 nor-
mal Karyotype B-ALL (the latter does not exclude sub-
karyotypic rearrangement). The AML patient cohort
consisted of 48 children consecutively admitted to the
Pediatric Oncologic Department at the University of
Padua (Padova, Italy) from 2000 to 2014 with the diag-
nosis of AML. Patients were molecularly diagnosed as
previously described [12] and 8 carried the FLT3-ITD, 5
the Inv(16)CBFB-MYH11, 8 harbored the t(8;21)AML1-
ETO, 12 MLL-rearrangements, and 12 were found
negative for the molecular markers screened. All the
procedures were approved by the local institutional
review boards, and the study was considered exempt
from review at UCLA.
Cloning and cell culture
RS4;11 and MV4;11, (MLL-AF4-translocated; ATCC CRL-
1873 and CRL-9591), REH (TEL-AML1-translocated; CRL-
8286), 697 (E2A-PBX1-translocated), Nalm-6, and 70Z/3
(ATCC TIB-158) murine pre-B cell leukemic cell line, and
the HEK 293 T cell line (ATCC CRL-11268) were grown as
previously described [5, 13]. mmu-miR-155 formatted siR-
NAs were cloned into BamHI and ApaI or XhoI in the
pHAGE2-CMV-ZsGreen-WPRE vector [5]. To determine
the 5′ and 3′ transcript ends of the lincRNAs, we per-
formed RACE (Rapid Amplification of cDNA Ends) using
FirstChoice RLM-RACE kit (Ambion). Using the sequence
information from 5′ and 3′ RACE products, we cloned full
length transcripts into an MSCV viral vector, as described
previously. Primer sequences used in cloning are listed in
Additional file 1: Table S1. For CRISPR-Cas9 mediated tar-
geting, guide RNAs were designed using the Zhang lab
website (http://crispr.mit.edu/) [14]. Guide RNA sequences
are listed in the Additional file 1: Table S1. Lentiviral pro-
duction was done in HEK293T cells using the helper plas-
mids pMD2G and psPAX2. REH cells were spin-infected at
30 °C for 90 min in the presence of polybrene. Cells were
selected with 5 μg/mL of puromycin for 7 days. Cell culture
was performed as previously described [15]. Flow cytometry
was used to detect apoptosis using Annexin V staining [5].
The paired gRNA MSCV retroviral vector (Manuscript
in preparation) was constructed via standard cloning
techniques to contain two U6-gRNA cassettes in tandem
followed by a EFs-mCherry reporter cassette, with each
of the three cassettes separated by a short spacer sequence.
The hU6 promoter, gRNA scaffold, and EFs promoter ele-
ments were derived from the pLentiCRISPRv2 vector [16].
The mU6 promoter was designed from the GenBank se-
quence NC_000076.6 (nt 79,908,880–79,909,195). A silent
mutation was incorporated into the mCherry reporter
element [17] to remove an internal BbsI restriction site.
The 20-nt gRNA sequences flanking a 3.1–3.8 kb region
(encompassing the first two exons) of mouse Casc15
(2610307P16Rik) were designed using sgRNA Scorer with
CasFinder [18]. Detailed methods are available upon
request.
Transduction and cell sorting
Lentivirus and MSCV-based retroviral vectors were
produced to generate knockdown and overexpression
constructs as previously described [15, 19]. 5.0 × 10^5 cells
were spin-infected twice at 30 °C for 90 min in the presence
polybrene (4 μg/mL). Transduced cell lines were sorted for
GFP positivity using a BD FACSAriaI/II cell sorter.
RT-qPCR
RT-qPCR was performed as previously described [19, 20].
For AML patient samples RT-qPCR experiments were car-
ried out using SYBR Green PCR Master Mix (Applied Bio-
systems) with an ABI 7900 Real-Time PCR System
(Applied Biosystems). Beta-glucuronidase (GUS) was used
as endogenous control. PCR reaction was performed in
three replicates, the comparative threshold cycle (dCt)
method [21] was used to analyze results. For all other as-
says, the results were expressed as fold-change with
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normalization to GAPDH or Actin. Primer sequences used
are listed in Additional file 1: Table S1. Primer set #1 for
CASC15 was used for all assays except for those with
enforced overexpression of the long isoform.
Microarray data analysis
RNA samples from RS4;11 control and siRNA-knockdown
cells were DNAse-treated and column purified using
RNeasy MiniElute Cleanup Kit. Samples were hybridized at
the UCLA microarray core facility using Affymetrix HG-
U133_Plus_2 microarray. The Affymetrix raw data files (.cel
files) were loaded into the R program for quality control
analysis. Additionally, raw hybridization intensities were
normalized using the MAS5 method the Affy package in R.
Normalized values were sorted by detection p-value ≤0.05.
Differential expression analysis was performed using un-
paired Bayesian comparison model (CyberT Website) [22].
Genes with a PPDE ≥99% and a fold change ≥2 was used
for the further analysis. For the analysis of REH control and
knockout cells, we utilized a slightly different analysis. For
differential analysis the raw data files were uploaded into
the R environment and analyzed using the R library of
Linear Models for Microarray Data (LIMMA). Pairwise
comparison and eBayes fit was carried out [13] Ana-
lysis of differentially expressed genes was carried out
using WebGestalt and GSEA [23, 24]. All data files
are available in the NCBI Gene expression Omnibus
database under accession number GSE101149.
Microarray data deposited in NCBI’s Gene Expression
Omnibus database (GEO; http://www.ncbi.nlm.nih.gov/
geo/) through the GEO accession number GSE17459
[25], 33 ETV6-RUNX1, 7 BCR-ABL, 31 DS-ALL, and 31
hyperdiploid ALL patients) and GSE75461 [26] (16
RUNX1-RUNX1T1, 8 FLT3-ITD, 4 CBFB-MYH11, 7
MLL-rearranged, 24 Negative, 7 DEK-NUP214, and 19
NUP98-translocated patients) were used to validate
CASC15 expression levels in these two independent co-
horts of B-ALL and AML pediatric patients, respectively.
Bone marrow transplant
As previously described, 5-FU enriched bone marrow
was spin-infected twice with MGP vector or M-Casc15-
G [27]. Lethally irradiated recipient mice were injected
with transduced donor bone marrow at least 6 h after ir-
radiation. 8 mice were used per group. These mice were
bled every 4 weeks post transplantation. All mice were
housed under pathogen free conditions at the University
of California, Los Angeles.
Flow cytometry
Bone marrow, blood and spleen were collected from the
mice at 16–27 weeks post-transplantation. Cells were
lysed in RBC (red blood cell) lysis buffer. Fluorochrome
conjugated antibodies were used for staining (Biolegend).
After 30–40 min of staining at 4 °C, cells were washed
twice with PBS and fixed with 1% PFA in FACS buffer.
Flow cytometry was performed at the UCLA Jonsson
Comprehensive Cancer Center (JCCC) and at the
BROAD Stem Cell Research Flow Core. Analysis was
performed using FlowJo software. A list of antibody
combinations used to define hematopoietic subsets is
provided in Additional file 2: Table S2.
CFU assay
5-Fluorouracil treated mice were sacrificed after 5 days
and the bone marrow was plated in media supplemented
with IL-3, IL-6 and mSCF (MethoCult 03434). After
24 h of plating, the bone marrow was infected twice with
retroviruses expressing the empty MGP vector or
CASC15/Casc15. GFP + cells were sorted and plated at
low concentration on methylcellulose medium contain-
ing mSCF, mIL3, hIL-6 and hEpo.
Luciferase assay
Approximately 2000 bp upstream from the transcription
start site of SOX4 was cloned upstream of firefly lucifer-
ase reporter gene in the pGL4.11 vector. pGL4.75 Renilla
luciferase vector was used for normalization. HEK 293 T
cells were transfected with the pGL4.75 and pGL4.11
containing reporter vectors at a 1:10 ratio (10 ng:100 ng),
along with a combination of pCMV (empty or YY1:
Origene-SC118004) and MSCV (empty or CASC15) vec-
tors at a 1:5 ratio (10 ng:50 ng), or a modification
thereof. BioT (Bioland Scientific LLC) was used in 24-
well plates as per the manufacturer’s instructions. Cells
were lysed after 36–48 h and supernatant lysate was col-
lected as per manufacturer’s instructions (Promega). The
dual luciferase assay kit (Promega) was used as sub-
strates for Renilla and firefly luciferase activity. The ratio
of firefly to Renilla luciferase activity was calculated for
all samples and normalized to the vector control.
Cell fractionation
Cells were pelleted and resuspended in NP-40 lysis buf-
fer (0.5% NP-40, 10 mM Tris (pH 7.4), 10 mM NaCl,
3 mM MgCl2, and 1 mM DTT), following which they
were incubated on ice for 5–10 min [5]. Suspension was
spun at 1200 rpm at 4 °C for 5 min. Supernatants con-
sisting of the cytoplasmic fraction were transferred to a
new tube without disturbing the nuclear pellet. Each
fraction was resuspended in Trizol and RNA extractions
were carried out.
RNA immunoprecipitation (RIP)
HEK 293 T cells were grown in a 10 cm plate and trans-
fected with 7.5 μg of MSCV control or CASC15 plasmid
and 7.5 μg of pCMV control or YY1 plasmids with Bio-T
transfection reagents. RIP was done as previously described
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[3]. The procedure was carried out under RNAse-free con-
ditions. 10 million cells were harvested and incubated for
20 min on ice in 2 ml of nuclear isolation buffer (1.28 M
sucrose, 40 mM Tris HCL pH 7.5; 20 nM MgCl2, 4% triton
X100), 2 ml of PBS and 6 ml of water. Nuclei were pelleted
and resuspended in 1 ml of RIPA (protease inhibitor
added). The lysate was homogenized for 15–20 strokes with
the Dounce homogenizer and centrifuged for 13,000 rpm
for 10 min to pellet the debris. Input fraction was removed
for RNA and protein isolation. The rest of the supernatant
was pre-cleared with normal IgG (1 μg) and protein A/G
plus beads (Santa Cruz) for 1 h at 4 °C. Beads were pelleted
by centrifugation 2500 rpm for 5 min 4 °C. Pre-cleared lys-
ate was divided into two and incubated overnight with gen-
tle rotation at 4 °C with the YY1 antibody (Rabbit mAb
#2185: Cell signaling) and the normal IgG. A/G plus agar-
ose beads were added and incubated for another 1–2 h.
Beads were pelleted and washed 3 times with RIPA buffer
and once with PBS. Supernatant was divided into 3:1 ratio
for RNA and protein extraction. Mouse monoclonal anti-
YY1 was used for the western blot (Abgent: AM2231b) on
the immunoprecipitate.
Results
CASC15 is overexpressed in acute leukemia with RUNX1
translocations and encodes multiple splice variants
In our previous study, we identified CASC15 as a dif-
ferentially expressed lncRNA between three subtypes of
pediatric B-ALL [5]. CASC15 showed a significant
variation in expression level depending on the subtype
of B-ALL in a larger set of B-ALL cases by RT-qPCR
(Fig. 1a, 1-way ANOVA, p < 0.02). Both ETV6-RUNX1
and E2A-PBX subtypes had significantly higher CASC15
expression compared to the BCR-ABL subtype (Fig. 1a).
We also quantified CASC15 expression in 48 bone mar-
row aspirates from pediatric acute myeloid leukemia
(AML) that showed 4 different translocations (Fig. 1b).
Overall expression of CASC15 showed a trend toward
higher expression in samples with t(8;21) translocation.
However, statistical significance is reached only when
compared to the samples with inv.(16) (Fig. 1b). To val-
idate higher CASC15 expression in t(8;21) and t(12;21)
rearranged leukemia, we analyzed two datasets deposited
in NCBI’s Gene Expression Omnibus database (GEO)
(N = 102 ALL, N = 85 AML; GSE17459 and GSE75461)
[25, 26]. CASC15 was upregulated in ETV6-RUNX1-
translocated patients compared to those with Down Syn-
drome ALL (DS-ALL) and hyperdiploid ALL (Additional
file 3: Figure S1a; 1-way ANOVA, p < 0.01). In AML pa-
tients, we confirmed CASC15 upregulation in RUNX1-
RUNX1T1-translocated patients compared with those
with inv(16) and DEK-NUP214 translocations (Additional
file 3: Figure S1b). It is interesting to note that the expres-
sion of CASC15 is highest in AML cases with t(8;21), and
ALL cases with t(12;21), which have the common trans-
location partner AML1/RUNX1. CASC15 expression was
not statistically associated with survival by Kaplan-
Meier analysis or in a multivariate regression model
(Additional file 3: Figure S1f).
To fully characterize the transcript structure of CASC15,
we carried out 5’RACE and 3’RACE (Rapid Amplification
of cDNA Ends) (Additional file 3: Figure S1c-e). Using the
sequence information from the 5′ and 3′ RACE products,
we cloned short (S) and a long (L) isoforms of the full
length CASC15 transcripts. The CASC15 (L) transcript is
~1634 nucleotides in length derived from 11 exons, while
the CASC15 (S) transcript is ~1193 nucleotides in length
derived from 7 exons (Additional file 3: Figure S1g and
Additional file 1: Table S1). ChIP-Seq data at the CASC15
locus obtained from the Encode project showed that the
chromatin signatures consisted of H3K4me3, usually
present in promoter regions, and H3K36me3, correspond-
ing to transcribed gene bodies indicating that it is a
transcriptional element (Fig. 1c) [1]. Inspection of the anno-
tated mouse transcriptome revealed the presence of a long
non-coding RNA (RIKEN cDNA 2610307P16) sharing 64%
similarity with human CASC15, with 86% sequence identity
at the 5′ end (Fig. 1c). Subcellular fractionation experi-
ments revealed that CASC15 is predominantly a nuclear-
localized lncRNA in all B-ALL cell lines tested (Additional
file 3: Figure S1i-k). In this study, we utilized NALM6,
REH, and RS4;11 cells, which show low (NALM6) and
high (REH and RS4;11) levels of CASC15 expression,
to analyze gain-of-function and loss-of-function phe-
notypes, respectively.
CASC15 overexpression opposes cellular proliferation and
promotes myeloid bias in vivo
To examine the effects of CASC15 gain of function,
murine Casc15 (Additional file 3: Figure S1h) was cloned
into a MSCV based dual promoter vector. Indicating a
conserved function, enforced expression of either the
murine or human lncRNA in mouse pre-B cell line 70Z/
3 resulted in increased apoptosis at basal levels and after
prednisolone treatment (Fig. 2a, b). In human NALM6
cells, the effects were less pronounced (data not shown).
In contrast to overexpression, knockdown of CASC15
resulted in decreased levels of prednisolone-induced
apoptosis in RS4;11 cells (Data not shown).
To examine the role of CASC15 in the hematopoietic
system, we undertook gain-of-function studies in pri-
mary bone marrow cells. Enforced expression of Casc15
in 5-FU enriched bone marrow resulted in decreased
overall colony formation in a methylcellulose assay
(Fig. 2c, d). Next, we transplanted 5-FU enriched
bone marrow transduced with retrovirus expressing
Casc15 into lethally irradiated recipient mice. FACS
analysis of peripheral blood from mice with Casc15
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overexpression showed overall decreased engraftment
(Fig. 2e, f ) and increased myeloid cells as a percent-
age of the GFP+ population (Fig. 2h). This phenotype
was persistent and the relative myeloid bias was
maintained in Casc15 expressing cells throughout the
course of the experiment. At the end of the experi-
ment, hematolymphoid organs were analyzed, reveal-
ing overall reduced engraftment, and a myeloid bias
to development (Fig. 2i-j; Additional file 4: Figure
S2c, S2i). Given the relative decrease in bone marrow
B-cells, we analyzed the developmental pathway of B-
cells in the bone marrow [28]. Among the Hardy
fractions, we observed an overall decrease in the
frequency of cells in all fractions with a significant
decrease in fractions B, D and E/F, but no changes in
earlier precursors (Additional file 4: Figure S2e-g).
These findings indicate that enforced expression of
Casc15 causes an overall reduction in hematopoiesis,
with the highest reduction in B-cell development.
Taken together, our findings imply that Casc15 is
pro-apoptotic and reduces hematopoietic engraftment,
particularly B-cell development, in vivo.
CASC15 regulates the expression of SOX4
Some lncRNAs regulate the expression of chromosomally
neighboring genes - a phenomenon typically observed
Fig. 1 CASC15 expression is highest in acute leukemia samples that carried a translocation involving the RUNX1/AML1. a RT-qPCR of the B-ALL
patient bone marrow samples using primer set #1 normalized to Actin, showing differential expression between cytogenetic subtypes based on
translocations (n = 125). Comparisons were made using 1-way ANOVA (p < 0.02) and a two-tailed T-test; statistically significant differences are
denoted as follows: P < 0.005 (**)). b RT-qPCR analysis of CASC15 expression in different molecular and cytogenetic subtypes of AML patient
samples, using primer set #1 and normalized to GUS (n = 48). Comparisons were made using a two-tailed T-test. c Top: Schematic showing the
genomic conservation of the syntenic block among vertebrates. Highly conserved region of the human CASC15 was used for the analysis. Bottom:
Chip-seq histone modification map from the ENCODE/Broad institute, taken from UCSC genome browser, shows H3K4me3 and H3K36me3
patterns at the SOX4 and CASC15 locus in two different cell types indicating active transcription of the lncRNA
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when positional conservation is present in vertebrate spe-
cies. The immediately adjacent gene to CASC15, SOX4, is
a transcription factor that is involved in B- cell develop-
ment as well as B- cell malignancies. In B-ALL patient
samples, SOX4 and CASC15 had a positive correlation in
B-ALL with TEL-AML1 translocations with an R2 value of
0.324 (Additional file 5: Figure S3b). We also observed





















































































































































































































Fig. 2 Over-expression of CASC15 leads to increased apoptosis in B-ALL cells and myeloid expansion in mice. a RT-qPCR of mouse pre-B 70Z/3
cell line transduced with either human CASC15(s) or murine Casc15. b Annexin V staining of 70Z/3 stably transduced with CASC15(S) and mouse
CASC15, either at baseline (DMSO) or treated with prednisolone (concentrations as indicated). c RT-qPCR or primary murine bone marrow cells
transduced with murine Casc15. d Methylcellulose colony formation assay using MYC (positive control) or murine Casc15. e-f FACS analysis of
peripheral bleed from mice 4 weeks after bone marrow transfer showing successful engraftment and transduction (GFP+) in vector (e) and
CASC15 (f) over expression mice. g RT-qPCR showing Casc15 overexpression in bone marrow at 16 weeks after transplantation. h FACS analysis of
peripheral bleeds from the mice 4–20 weeks after bone marrow transplantation showing increased percentage of myeloid cells in the Casc15
overexpression mice. i FACS analysis of peripheral blood showing percentage of B220+ and CD11b + cells at 16 weeks post-transplantation. j
FACS analysis of bone marrow showing percentage of GFP+, B220+ and GFP+, CD11b + cells at 16 weeks post-transplantation. In experiments
depicted for g-j, n = 8 mice/group, and experiments were repeated three times. Statistically significant differences are shown as follows: p < 0.05
(*); p < 0.01 (**); p ≤ 0.0005 (***). All qPCR analyses for CASC15 were performed with primer set #1 and normalized to GAPDH or actin, except
where otherwise noted. Experiments were repeated three times for validation
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in their expression levels in both B-ALL cell lines (Fig. 3a)
and AML cell lines (Fig. 3b). CASC15 expression was
noted to be highest in REH, KASUMI, SKNO1, that carry
RUNX1 translocations, consistent with the primary pa-
tient data, as well as in THP1 cells that carry a tran-
slocation of MLL. Confirming the idea of a positive
correlation, RNA-sequencing data from the Cancer Cell
line Encyclopedia (CCLE) [29] showed that B-ALL and
AML cell lines showed a strong positive correlation be-
tween the expression of CASC15 and SOX4, while
DLBCL and non-hematopoietic tumor cell lines did not






















































































































































































































































































Fig. 3 CASC15 expression is strongly correlated with and regulates SOX4 expression. a-b Correlation between CASC15 and SOX4 expression in
various B-ALL and AML cell lines. c-d RT-qPCR of CASC15 and SOX4 in REH cells (c) and RS4;11 (d) following knockdown of CASC15 using three
independent siRNA sequences. Statistically significant differences from control are noted as follows: p < 0.05 (*); p < 0.01 (**); p < 0.0005 (***). e-f
Western blot analysis of SOX4 protein levels in RS4;11 (e) and REH (f) cell lines upon CASC15 knockdown. (g) RT-qPCR of CASC15 and SOX4 in REH
cells following CRISPR/Cas9 mediated targeting. Statistically significant differences from control are denoted as follows: p < 0.05 (*); p < 0.01 (**).
h RT-qPCR of murine Casc15 and Sox4 on RNA extracted from FACS-purified hematopoietic progenitor fractions shows a rough correlation in their
expression, particularly in the B-cell subsets. i RT-qPCR for murine Sox4 following transduction of bone marrow cells with murine Casc15 shows
upregulation of expression. All qPCR analyses for CASC15 were performed with primer set #1 and normalized to GAPDH or actin, except where
otherwise noted. Experiments were repeated three times for validation. Experiments were repeated three times for validation
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causative relationship existed between the expression of
CASC15 and SOX4, we designed and validated siRNAs to
knockdown CASC15 in REH and RS4;11 cells. We noted
that knockdown of CASC15 also resulted in a knockdown
of SOX4 (Fig. 3c-f). To further characterize this relation-
ship, we edited CASC15 by CRISPR/Cas9 [30, 31]. We tar-
geted the transcription start site, intron-exon boundaries
and the polyadenylation signal with a series of guide RNAs
(C1, C9, C11, and C12) (Additional file 5: Figure S3e and
Additional file 1: Table S1). Heteroduplex DNA that re-
sulted from Cas9:sgRNA-mediated cleavage was observed
by the endonuclease T7 assay (Additional file 5: Figure
S3g-j). RT-qPCR data showed that targeting of specific
splice junctions resulted in down regulation of CASC15 in
REH cells (Fig. 3g) and RS4;11 cells (Additional file 5:
Figure S3f). Concurrent with downregulation of CASC15,
CRISPR/Cas9 mediated knockout also lead to downregu-
lation of SOX4 (Fig. 3g). To assess species conservation,
we sorted mouse bone marrow into progenitor subsets
and examined Casc15 and Sox4 by RT-qPCR [28, 32].
Casc15 is expressed in all the hematopoietic compart-
ments tested, however, the highest expression was ob-
served at the common lymphoid progenitor (CLP) stage
and pro-B to pre-B stages (data not shown, Fig. 3h and
Additional file 6: Figure S4). Sox4 shows a similar expres-
sion profile in committed B-cell progenitors (Fig. 3h).
Complementing this data, bone marrow transduced with
a retrovirus overexpressing Casc15 demonstrated in-
creased Sox4 levels (Figs. 2c and 3i). Together these data
strongly suggest that CASC15 regulates SOX4 levels,
particularly in the loss-of-function context.
To further confirm our findings, we designed a second
CRISPR/Cas9-based method to knockout Casc15. For this
purpose, we designed and built a MSCV-based retrovirus
that contains a mCherry reporter and two U6-driven cas-
settes for the expression of small guide and scaffold RNA.
To knockout Casc15, we targeted exons 1 and 2 with a
series of small guide RNAs. Three guide RNAs (1,2, and 4
on the 5′ end; 6, 8, 9 on the 3′ end) were designed on
each side of the knockout region (Fig. 4a). Next, we
retrovirally transduced murine 70Z/3 cells with constructs
containing pairs of guide RNAs, resulting in bulk trans-
ductants, that were subsequently subjected to single
cell cloning (Fig. 4b). Measurement of mCherry fluor-
escence by FACS in the bulk transductants confirmed effi-
cient transduction (Fig. 4c). To genotype the bulk
transductants, we utilized two sets of primers, one to detect
the deleted allele (DEL) and the other to detect the wild-
type allele (WT). As anticipated, the initial bulk transduc-
tants showed the presence of both alleles of Casc15, reflect-
ing a mixture of cells with wild-type, heterozygous, and
homozygous deletion of Casc15 (Fig. 4d). Then, we sub-
jected the bulk transductants to single cell cloning by limit-
ing dilution plating. As can be seen, the single cell clones
retained strong mCherry fluorescence (Fig. 4e), and we
identified several clones that contained a homozygous
deletion of Casc15, including the clones shown (Fig. 4f). As
expected, RT-qPCR showed a complete absence of Casc15
and all the clones showed reduced expression of Sox4,
which was statistically significant except in one case. Hence,
we have confirmed a causal relationship between Casc15
and Sox4 using three different knockdown/knockout
systems.
CASC15 knockdown leads to enrichment for the
transcriptional targets of YY1
To gain insight into the molecular mechanism by which
CASC15 functions, we examined gene expression in RS4;11
cell lines where Casc15 was knocked down (Fig. 5a). Upon
siRNA mediated knockdown (CASC15 KD) of CASC15,
3289 microarray probes showed differential expression with
PPDE >99%, fold change >2. In agreement with the RT-
qPCR, SOX4 was downregulated in CASC15 KD cell lines,
and gene set enrichment analysis [33] demonstrated that
genes that are known to be downstream of SOX4 [34] were
also regulated by CASC15 knockdown, confirming a down-
stream effect on SOX4 transcriptional activity (Fig. 5i-j). To
validate the microarray, RT-qPCR was used to confirm the
expression pattern of three genes that were highly differen-
tially regulated in RS4;11 (Fig. 5b-d) and REH (Fig. 5e-g)
CASC15 KD cell lines. Functional enrichment of differen-
tially expressed genes was carried out using WebGestalt.
In parallel, we also carried out microarray analysis of REH
cells with CRISPR/Cas9-mediated deletion of CASC15
(CASC15 KO; Additional file 7: Figure S5). Significant
changes were seen in several categories of genes in both
datasets when analyzed by WebGestalt [35] (Additional
file 7: Figure S5a). Because of CASC15’s nuclear
localization, we hypothesized that the downstream effects
may be mediated by a transcription factors. This analysis
led us to a list of transcription factors that were putatively
responsible for the observed changes in gene expression
in both REH and RS4;11 cell lines (Fig. 5h). Amongst
these genes, the YY1 transcription factor showed consist-
ent changes between cell lines, was statistically enriched,
and is known to bind to the SOX4 promoter [36]. GSEA
analysis confirmed that both SOX4 and YY1 transcrip-
tional targets [34, 37] are also enriched in our differentially
expressed gene set (Fig. 5k-i and Additional file 7: Figure
S5c), reinforcing the idea that CASC15 may act through
transcriptional regulation of a specific transcription factor,
such as YY1, with a downstream effect on SOX4.
YY1 mediated transcriptional regulation of SOX4
promoter is promoted by CASC15
To further elucidate the relationship of CASC15 and
YY1 to regulation of SOX4 promoter, we cloned ap-
proximately 2000 bp upstream region of the SOX4
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promoter into the luciferase reporter vector, pGL4.11
[38]. This region contains three putative binding sites
for the transcription factor YY1 [36]. Dual luciferase re-
porter assays in HEK 293 T cells, with constitutive ex-
pression of CASC15, caused increased SOX4 promoter
activity (Additional file 7: Figure S5d). Notably, when
CASC15 and YY1 were co-expressed, SOX4 promoter ac-
tivity was further enhanced (Fig. 6a). Transient transfec-
tion of 293 T cells consistently led to expression of YY1
mRNA, CASC15 RNA, and YY1 protein (Fig. 6c-e). In
addition, in these transient transfection assays, SOX4
mRNA was upregulated, indicating an effect on the en-
dogenous SOX4 locus (Fig. 6b). These data show a direct
functional impact of CASC15 and YY1 on transcriptional
regulation of SOX4.
Recent work has indicated that one mechanism of
lncRNA-mediated gene regulation is via interaction with
transcriptional and/or epigenetic regulators, such as the
Polycomb repressor complex or indeed YY1 itself [39, 40].
Furthermore, given that YY1 has a role in regulating PRC
and can tether non-coding RNA to chromatin [41, 42], we
performed an RNA immunoprecipitation (RIP) assay using
Fig. 4 Casc15 knockout in murine cells results in Sox4 downregulation. a Schematic of Casc15 gene in the mouse showing exonic
sequences 1 and 2, along with the placement of short guide RNAs to induce deletion of these exons. b Schematic of approach to
generation of genomic-level knockouts of Casc15. c FACS analysis of mCherry expression ion bulk transductants from this approach.
d PCR analysis of mutant (DEL) and wild-type (WT) Casc15 alleles in bulk transductants cells. e FACS analysis of mCherry expression in
single cell clones generated by limiting dilution plating. f PCR analysis of mutant (DEL) and wild-type (WT) Casc15 alleles in single cell
clones generated by limiting dilution plating. g RT-qPCR analysis of Casc15 and Sox4 expression. Statistically significant differences
from control are noted as follows: p < 0.05 (*); p < 0.01 (**)
Fernando et al. Molecular Cancer  (2017) 16:126 Page 9 of 15
anti-YY1 antibodies in 293 T cells transiently transfected
with combinations of YY1 and CASC15 (Additional file 7:
Figure S5e). Following successful transfection and immu-
noprecipitation of YY1, we found that CASC15 was mod-
estly enriched in RIP specifically with the anti-YY1 antibody
(Additional file 7: Figure S5e). However, RIP assays
performed against endogenous YY1 in REH cells were un-
successful, likely due to a low level of endogenous YY1
under baseline growth conditions (data not shown). None-
theless, our data shows that YY1 enhances transcription
from the SOX4 promoter, and that CASC15 appears to en-
hance transcriptional upregulation of SOX4mRNA.
Fig. 5 CASC15 knockdown leads to enrichment for the transcriptional program of SOX4 and YY1. a Unsupervised hierarchical gene clustering of
differentially expressed genes upon CASC15 siRNA mediated knockdown in RS4;11 cells (PPDE >99%, fold change >2). b-g RT-qPCR confirmation
of differentially expressed genes from the microarray in RS4;11 (b-d) and REH (e-g) cell lines. h To narrow down transcription factors that might
be responsible for the observed changes in gene expression, we overlapped transcription factors that were associated with the differentially
expressed gene sets in CASC15 KD RS4;11 cells as well as CASC15 KO REH cells. Shown are the numbers of genes in the differentially expressed
gene set for each transcription factor that showed an association. i-j Enrichment plots from gene set enrichment analysis (GSEA). The differentially
regulated gene set from CASC15 KD RS4;11 cells showed a positive enrichment score when compared to genes up-regulated in ACC3 cells with
SOX4 knockdown (i; Enrichment Score = 0.5, FDRq = 0.0 and P value = 0.0), and showed a negative enrichment score when compared to genes
downregulated in ACC3 cells with SOX4 knockdown (j; Enrichment Score = −0.38,FDRq = .017 and P value = 0.01). k-l Enrichment plots from
gene set enrichment analysis (GSEA) showing that the differentially regulated gene set showed a positive enrichment score when compared with
upregulated genes upon YY1 knockdown (k; Enrichment Score = 0.5, FDRq = 0 and P value = 0.0) and a negative enrichment score with
downregulated genes upon YY1 knockdown (l; Enrichment Score = -0.39, FDRq = 0 and P value = 0.0)
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Discussion
The field of lncRNA research has recently been growing
and the diversity of functions ascribed to lncRNAs in-
cludes transcriptional regulation amongst several others
[1, 3, 43]. Following up on our initial discovery of dys-
regulated lncRNA expression in B-ALL, we have now
characterized individual lncRNAs. Interestingly, the ex-
pression of CASC15 in B-ALL and AML samples was
highest in cases that carried a translocation involving the
RUNX1/AML1. RUNX1 mutations and translocations
are amongst the most commonly seen mutations in
hematologic malignancies [44–46]. All of these alter-
ations lead to loss-of-function of RUNX1 by a variety of
mechanisms. It will be of interest to examine CASC15 in
other leukemia subtypes with RUNX1 loss-of-function,
and these experiments are the focus of future studies.
Analyses of CASC15 in adult B-ALL, AML, and correla-
tions with clinicopathologic indicators will be important
in defining a prognostic role for this lncRNA.
Here, we also identified a mouse transcript that shows
sequence and functional conservation with human
CASC15. Concordant with an overall role for CASC15
as a tumor suppressor gene, our data also showed that
overexpression of CASC15 led to increased cell death in
leukemia cell lines following prednisolone treatment.
Additionally, primary hematopoietic cells that were
transduced with mouse and human CASC15 showed
decreased colony formation and decreased levels of
reconstitution in bone marrow transplantation assays.
All of these findings suggest that CASC15 expression
may limit cell proliferation.
However, the high expression of CASC15 in RUNX1-
translocated cases is curious. Indeed, this might reflect a
differential function in cell proliferation versus differen-
tiation- with high CASC15 causing a block in differenti-
ation along with decreased proliferation. It is also
possible that CASC15 expression in leukemic cells sim-
ply reflects the stage of differentiation that they are
derived from. In hematopoiesis, the expression profile of
CASC15 shows a bimodal distribution, with a peak in
CLPs and a second peak in large pre-B-cells. Presum-
ably, constitutive overexpression of CASC15 prevents
the drop seen at the pre-pro-B-cell stage and causes the
observed myeloid bias and/or a block in B-cell develop-
ment in the transplanted mice. It is possible that the cel-
lular function of CASC15 in modulating cell survival is
also the basis of its function during development. Fur-
ther studies, for example, in mice with deletion of Bim
or overexpression of Bcl2, may help clarify the role of
CASC15 in differentiation versus cell survival.
Interestingly, our findings of reduced colony forma-
tion, reduced engraftment and myeloid bias have pa-
rallels with cellular and molecular phenotypes induced
by expression of the ETV6-RUNX1 fusion protein. For
Fig. 6 CASC15 regulates the activity of YY1 on the SOX4 promoter. a Transcriptional activity of SOX4 promoter upon CASC15 (L) and/or YY1
overexpression, as measured by dual luciferase assay. Luciferase values are normalized to the empty vector. b-d RT-qPCR with primers directed
against SOX 4 (b) CASC15 (c) and YY1 (d) and Western blot for YY1 (e) in 293 T cells transiently transfected with YY1 and CASC15. All qPCR
analyses for CASC15 were performed with primer set #1 and normalized to GAPDH or actin, except where otherwise noted. Experiments were
repeated three times for validation
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example, a series of studies have shown that the number
of colonies produced by bone marrow transduced with
ETV6-RUNX1 was 10-fold reduced compared to control,
showed myeloid bias, and showed an initial selective dis-
advantage in reconstitution of bone marrow [47–49].
Gene expression analysis has shown that ETV6-RUNX1
targets by ChIP-seq are enriched for inhibitors of prolif-
eration pathways [50]. Hence, the mechanisms under-
lying transformation by ETV6-RUNX1 are complex, and
require cooperating mutations and/or epigenetic events.
Our data also demonstrated knockdown of lncRNA
utilizing the CRISPR-Cas9 system with a single guide
RNA. Since we could not utilize traditional sgRNA tar-
geting approaches for protein coding genes, which rely
on generating frameshift mutations, we targeted tran-
scription start, intron-exon junctions and poly A signal
sites. Here, targeting three different intron-exon junc-
tions in the CASC15 transcript was sufficient to cause
knockdown. Other manuscripts that successfully report
lncRNA knockdown using CRISPR/Cas9 have utilized
different strategies [51, 52]. By using this simple and
very straightforward technique for designing small gen-
omic RNAs (sgRNAs), this promising new technology
can be used in generating lncRNA knockouts, and to
study the function of lncRNAs in high-throughput
screening approaches using a single sgRNA targeting in-
dividual lncRNAs. We also validated a more traditional
strategy to create deletions of segments of DNA using
CRISPR/Cas9 mediated targeting. By generating a single
retroviral vector that can successfully carry two sgRNAs,
we have developed a high-titer retroviral reagent for effi-
cient knockdown of lncRNA expression. However, it
should be noted that all of these methods create a mix-
ture of heterozygous and homozygous knockouts cells,
and hence the downstream confirmation of knockout re-
mains important.
In line with a function in transcriptional regulation,
genes that neighbor CASC15 were downregulated by
CASC15 knockdown. However, the most consistent re-
sult to emerge from this study was the strong positive
relationship between CASC15 and SOX4. Found to be
strongly correlated in primary human leukemic cells and
in mouse cells, as well as in experimental datasets with
knockdown and overexpression of CASC15/Casc15, our
findings are consistent with studies that demonstrate
that the expression of lncRNAs is tightly coupled to that
of neighboring genes [2]. Moreover, CASC15 knockdown
led to altered expression of genes that were enriched for
transcriptional targets of SOX4. These findings suggest
that one of the major functions of CASC15 may be to
regulate the expression of SOX4. A potential mechanism
is suggested by the fact that CASC15 knockdown by any
method led to alterations in the global transcriptome
regulated by the transcription factor YY1. Our further
functional analyses revealed that CASC15 promotes
YY1-mediated transcriptional activity at the SOX4 pro-
moter. It will be of great interest to determine if
CASC15 globally modulates which promoters YY1 binds
to, and whether this occurs through direct interaction or
via modulation of general transcriptional complexes.
SOX4 is thought to function as an oncogene in acute
leukemia, particularly in the myeloid lineage [8, 53–55].
SOX4 expression is thought to support self-renewal
of leukemic cells and to inhibit differentiation in C/
EBP α-mutant AML [55], support PI3K/Akt signaling
in BCR-ABL-driven B-ALL [53], and cooperate with Pu.1
haploinsufficiency in murine leukemia [54]. However, in
this study, Casc15 increased Sox4 but caused decreased
engraftment in bone marrow transplantation experiments.
This may also be in line with patient-based studies that
have shown that elevated expression of SOX4 leads to
better survival, decreased disease progression, and re-
duced tumor cell invasiveness in several different cancers
[56–58]. Hence, both CASC15-mediated regulation and
SOX4 function may be dependent on the transcriptional
context of the leukemic cell, and this has not been
previously assessed in B-ALL with RUNX1 or MLL
translocations. Further work to characterize the nor-
mal function of CASC15 in hematopoietic develop-
ment using germline murine knockout models or via
CRISPR/Cas9 deletion in bone marrow cells will help
illuminate its role in hematopoiesis.
Conclusion
Our work demonstrates cellular roles for a lincRNA iden-
tified in B-ALL. Additionally, we demonstrate a novel
method of lincRNA knockdown by targeting splice junc-
tions with the CRISPR/Cas9 system. At the molecular
level, it appears that CASC15 works by regulating
expression of SOX4, likely by modulating the activity of
transcription factors such as YY1. Our work opens the
door to more extensive studies of lincRNAs in B-ALL and
hematopoiesis. By better understanding lincRNA medi-
ated actions in malignant gene expression programs, we
will be better able to design prognostic indicators and
therapeutic strategies targeting or harnessing lincRNAs.
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Additional file 1: Table S1. Primers, siRNAs, guideRNAs and RACE
sequences. (PDF 154 kb)
Additional file 2: Table S2. Antibodies used for FACS analyses.
(PDF 105 kb)
Additional file 3: Figure S1. (A) CASC15 expression is higher in
RUNX1 translocated patients respect to other B-ALL subtypes with
aberrancies related to chromosome 21. Probe 229280_s_at, HGU133
plus 2 Affymetrix (DS-ALL, Down Syndrome) (1- way ANOVA,
p < 0.01). (B) CASC15 expression is higher in RUNX1 translocated
patients respect to other AML subtypes. Probe TC06000136.hg.1 HTA
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2.0 Affymetrix. (1- way ANOVA, p < 0.01). Comparisons were made
using a two-tailed T-test, statistically significant differences are
denoted as follows: ** P < 0.01. Source of data for (A) and (B): two
datasets deposited in NCBI’s Gene Expression Omnibus database
(GEO) (N = 102 ALL, N = 85 AML; GSE17459 and GSE75461) [25, 26].
(C) Diagram showing 5′ and 3′ RACE product aligned with Ref
sequence obtained from the UCSC genome browser. 5′ RACE primers
are shown in blue. Unannotated exons are shown in yellow. (D-E)
Gel showing 5 and 3′ RACE products. (F) Kaplan Meier survival
analysis for two patient groups (high and low CASC15 expressers)
shows that low CASC15 expression shows a trend towards worse
overall survival (Log Rank Test, P-value, n.s. p = 0.18). The two groups
were dichotomized based on two step cluster analysis using SPSS
software. (G) Schematic showing the exon-intron structure of the two
isoforms of CASC15 (H) Schematic showing the exon-intron structure
of the mouse Casc15. (I-K) RT-qPCR data showing expression of
CASC15 in cytoplasm and nuclear fractionations of from REH (I),
RS4;11 (J) and 697 cell lines (K). Abbreviations: WCL (whole cell lysate), C
(cytoplasmic fraction), and N (nuclear fraction). GAPDH and CELF4 were used
as positive controls for cytoplasmic and nuclear-localized mRNAs, respectively
[5]. 1 and 2 are biological replicates. (PDF 671 kb)
Additional file 4: Figure S2. (A) MTS assay showing no significant
difference in cell proliferation in CASC15(S) over expressing NALM6
cells. B) PI staining of CASC15(S) over expressing NALM6 cells,
showing no difference in the stages of cell cycle. C) FACS analysis
of peripheral bleeds from the mice 4–20 weeks after bone marrow
transplantation showing GFP positive cells as a percentage in the
control and Casc15 overexpression mice. Initial GFP positivity in the
engrafted bone marrow was similar in both groups. (D) Complete
blood counts (CBC) of control and Casc15 overexpression mice at
the week of 20 from the time of retro orbital injections. E) FACS
analysis of Hardy fractions showing overall decreased B-cell fractions in
Casc15 overexpression mice at 27 weeks after transplantation. (F-G) FACS
analysis of LIN- and LSK+ cells from the control and Casc15 over expression
mice showing no difference in those two populations. (H) Methylcellulose
Colony Formation assay showing reduced number of colonies in BM cells
with enforced expression of human CASC15. (I) FACS analysis of percentage
of GFP+, B220+ and CD11b + cells in the spleen at the week of 16 after
transplantation. Black circles, control mice; brown squares, Casc15-expressing
mice. Data are represented as individual data points and a mean (bar).
Statistical comparisons were completed using a two-tailed T-test; p < 0.05
(*); p < 0.01 (**); p ≤ 0.0005 (***). (PDF 89 kb)
Additional file 5: Figure S3. (A). RT-qPCR showing the expression of
PRL in RS4;11 cell line and LOC79217 in REH and RS4;11 cells. Statistical
comparisons were completed using a two-tailed T-test; p < 0.05 (*);
p < 0.01 (**); p ≤ 0.0005 (***). (B) Correlation between SOX4 and CASC15
expression in ETV6-RUNX1-translocated primary B-ALL samples (left
panel), B-ALL cell lines (middle panel) and AML samples (right panel). (C)
Correlation between SOX4 and CASC15 expression in publically available
datasets (Cancer cell line encyclopedia) [29] in AML cell lines (top left),
B-ALL cell lines (top right), DLBCL (bottom left) and other non-hematopoietic
cell lines (bottom right). High degrees of correlation are seen in AML and B-
ALL cell lines. (D) MTS assay showing no significant difference cell proliferation
upon CASC15 knockdown by siRNA 1-2in RS4;11 cell line. (E) Strategy
to knockout CASC15 using CRISPR/Cas9-mediated gene editing. Target
sites that were utilized are denoted, superimposed on the exon-intron
structure of CASC15. (F)RT-qPCR to measure CASC15 expression following
CRISPR/Cas9-mediated gene editing of CASC15 in RS4;11 cells. (G-J)T7
Endonuclease assay showing the presence of heteroduplex DNA
generated by CRISPR-Cas9-mediated cleavage at the transcription
start at exon 1 (C1) (G), splice junction at exon 9 (C9) (H), exon 11
(C11) (I) and poly A signal site (C12) (J). T7 enzyme cleavage is
detected by the presence of multiple bands in the C1, C9, C11 and
C12 integrated cells compared to the vector. (PDF 742 kb)
Additional file 6: Figure S4. (A, B) Schematics (A) and FACS plots (B)
showing the sorting strategy for B-cell progenitor fractions as per the
method of Hardy et al. [59, 60]. (PDF 250 kb)
Additional file 7: Figure S5. (A) Heat map comparison of gene
expression in REH cells transduced with LentiCRISPR versus those
transduced sgRNA against exons 1, 9 of CASC15 (See Fig. 3). Columns
represent technical replicates utilized with Affymetrix U133 human chip.
(B) Disease association analysis was carried out using Webgestalt,
http://www.webgestalt.org. Shown are the numbers of disease-
associated genes in each disease that showed a statistically significant
association with which the differentially expressed gene set in CASC15 KO REH
cells. (C) GSEA was performed on the differentially expressed gene set in
CASC15 KO REH cells, showing a significant association with the transcriptome
regulated by SOX4, as also noted in the RS4;11 KD cells (Fig. 4). Left panel:
Enrichment score (ES) -0.38 and FDRq = 0.017. Right panel: ES: −0.4526 and
FDRq = 1. (D) Transcriptional activity of the SOX4 promoter with increasing
levels of CAC15 transfected into HEK-293 T cells, as measured by dual
luciferase assay. (E) Results of RIP assay: Western blot characterization of
immunoprecipitate from YY1 pull-down (top panel) and RIP enrichment,
determined as RNA associated to YY1, relative to IgG control (bottom panel).
(PDF 546 kb)
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